A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab (bev) as a first-line therapy for patients with metastatic colorectal cancer

被引：0
|
作者：
Sato, Yasushi
Ohnuma, Hiroyuki
Hirakawa, Masahiro
Takahashi, Minoru
Osuga, Takahiro
Takada, Kohichi
Hayashi, Tsuyoshi
Sato, Tsutomu
Miyanishi, Koji
Takimoto, Rishu
Kobune, Masayoshi
Okita, Kenji
Furuhata, Tomohisa
Hirata, Koichi
Kato, Junji
机构：
[1] Sapporo Med Univ, Sch Med, Dept Med Oncol & Hematol, Sapporo, Hokkaido, Japan
[2] Sapporo Kyoritsu Gorinbashi Hosp, Div Gastroenterol, Sapporo, Hokkaido, Japan
[3] Sapporo Med Univ, Sch Med, Dept Surg Surg Oncol & Sci, Sapporo, Hokkaido, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期
关键词：
D O I：
10.1200/jco.2014.32.3_suppl.612
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
612
引用
收藏
页数：1
相关论文
共 50 条
  • [31] EFFECTIVENESS OF CHEMOTHERAPY WITH OXALIPLATIN, CAPECITABINE AND BEVACIZUMAB (XELOX plus BEV) IN SECOND LINE THERAPY OF METASTATIC COLORECTAL CANCER (MCRC)
    Arzykulov, Z.
    Chichua, N.
    Smagulova, K.
    Khamidullina, G.
    Mukanova, S.
    Suriya, K.
    ANNALS OF ONCOLOGY, 2010, 21 : 32 - 32
  • [32] Retrospective analysis of capecitabine and oxaliplatin (XELOX) plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer
    Uchima, Yasutake
    Nishii, Takafumi
    Iseki, Yasuhito
    Ishii, Mariko
    Hiramatsu, Soichiro
    Iwauchi, Takehiko
    Morimoto, Junya
    Kosaka, Kinshi
    Tei, Seika
    Takeuchi, Kazuhiro
    MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (01) : 134 - 138
  • [33] Capecitabine Plus Bevacizumab as First-Line Therapy for Patients with Metastatic Colorectal Cancer and Poor Performance Status
    Yamada, Yasufumi
    Yoshimatsu, Kazuhiko
    Yokomizo, Hajime
    Okayama, Sachiyo
    Satake, Masaya
    Ida, Arika
    Maeda, Hiroyuki
    Shiozawa, Shunichi
    JOURNAL OF NIPPON MEDICAL SCHOOL, 2021, 88 (05) : 496 - 499
  • [34] Capecitabine (X), irinotecan (I) and bevacizumab (A) as first-line therapy for patients (PTS) with metastatic colorectal cancer (MCRC): Preliminary phase II study results
    Semir, Beslija
    Maja, Banjin
    Nadja, Paraganlija
    Timur, Ceric
    Anes, Pasic
    Berisa, Salkic
    Anes, Sosevic
    Nermina, Obralic
    ANNALS OF ONCOLOGY, 2006, 17 : 127 - 127
  • [35] Impact of the addition of bevacizumab, oxaliplatin or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients.
    Landre, Thierry
    Aparicio, Thomas
    Ghebriou, Djamel
    Nicolas, Patrick
    Taleb, Cherifa
    Chouahnia, Kader
    Zelek, Laurent H.
    Des Guetz, Gaetan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [36] Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer
    Pander, Jan
    van Huis-Tanja, Lieke
    Bohringer, Stefan
    van der Straaten, Tahar
    Gelderblom, Hans
    Punt, Cornelis
    Guchelaar, Henk-Jan
    PLOS ONE, 2015, 10 (07):
  • [37] Phase II multicenter study of capecitabine plus oxaliplatin (XELOX) sequentially followed by capecitabine and irinotecan (XELIRI) in first-line therapy for metastatic colorectal cancer (MCRC)
    Cassinello, J.
    Alvarez, J. V.
    Garcia-Lopez, M. J.
    Pujol, E.
    Colmenarejo, A.
    De Segovia, F.
    Marcos, F.
    Filipovich, E.
    EJC SUPPLEMENTS, 2005, 3 (02): : 199 - 200
  • [38] Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    J Feliu
    J Barriuso
    British Journal of Cancer, 2011, 104 : 226 - 226
  • [39] Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer
    Bazarbashi, Shouki
    Aljubran, Ali
    Alzahrani, Ahmad
    Mohieldin, Ahmed
    Soudy, Hussein
    Shoukri, Mohammed
    CANCER MEDICINE, 2015, 4 (10): : 1505 - 1513
  • [40] Comment on 'Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer'
    Molina-Garrido, M. J.
    Guillen-Ponce, C.
    BRITISH JOURNAL OF CANCER, 2011, 104 (01) : 224 - 225
12345